Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Prostatic Neoplasms

Neoplasm Metastasis

Urologic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Neoplastic Processes

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urologic Diseases

Antineoplastic Agents

All Drugs and Chemicals

Anti-Inflammatory Agents

Micronutrients

Docetaxel

Prednisone

Sodium Selenite

Tubulin Modulators

Antimitotic Agents

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Biosyn

Dr. Sandy Srinivas

Selenium, in the form of inorganic Sodium Selenite, may be useful for treating existing prostate cancer. This idea is based on data from our laboratory showing that 1) prostate cancer cells are more sensitive to Selenium (Sodium Selenite)-induced apoptosis than normal prostate epithelial cells, 2) Selenite induces significant growth inhibition of well established prostate cancer tumors in mice at doses that have no detectable toxicity, and 3) Selenite disrupts AR signaling, and that the inhibition of AR expression and activity by Selenite occurs via a redox mechanism involving GSH, superoxide, and Sp1. Altogether, these findings suggest that Selenium may be useful in a variety of potential indications in the natural history of prostate cancer, including both hormone sensitive and castrate resistant prostate cancer, as a single agent, or in combination with radiation, chemotherapy or conventional hormone therapy. Selenite is a potential novel inhibitor of AR expression and function in prostate cancer.

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

Sandy Srinivas

Associate Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer	NCT01155791	Urologic Neopla... Prostate Cancer Prostate Cancer...	Docetaxel Biosyn Prednisone	18 Years -	Stanford University
Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer	NCT01155791	Urologic Neopla... Prostate Cancer Prostate Cancer...	Docetaxel Biosyn Prednisone	18 Years -	Stanford University

Spots Global Cancer Trial Database for prostate cancer metastatic disease